Retrieve available abstracts of 29 articles: HTML format
Single Articles
May 2025
LEE KW, Zang DY, Kim HD, Kim JW, et al Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in
combination with paclitaxel in patients with biomarker-selected metastatic
gastric cancer.
Br J Cancer. 2025 May 21. doi: 10.1038/s41416-025-03052. PubMedAbstract available
GROEN-VAN SCHOOTEN TS, Cabeza-Segura M, Ferreira RM, Martinez-Ciarpaglini C, et al Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies
global differences in immune subgroups and microbiome influence.
Br J Cancer. 2025;132:783-792. PubMedAbstract available
April 2025
SUN M, Gu Y, Wang J, Zhang Z, et al Smad4 loss identifies aggressive subtype with immunotherapy and anti-HER-2
treatment resistance in gastric cancer.
Br J Cancer. 2025 Apr 25. doi: 10.1038/s41416-025-03002. PubMedAbstract available
LI J, Tao M, Liu L, Liu C, et al Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell
treatment resistance in advanced gastric cancer.
Br J Cancer. 2025 Apr 17. doi: 10.1038/s41416-025-03015. PubMedAbstract available
LU J, Chen Y, Liu X, Wang J, et al Artificial intelligence-driven microRNA signature for early detection of gastric
cancer: discovery and clinical functional exploration.
Br J Cancer. 2025 Apr 15. doi: 10.1038/s41416-025-02984. PubMedAbstract available
March 2025
TSUTSUMI C, Ohuchida K, Yamada Y, Shimada Y, et al Claudin18.2-positive gastric cancer-specific changes in neoadjuvant
chemotherapy-driven immunosuppressive tumor microenvironment.
Br J Cancer. 2025 Mar 24. doi: 10.1038/s41416-025-02981. PubMedAbstract available
September 2024
CHEN C, Han J, He Q, Yao Q, et al Tumor-infiltrating immune cell profiles and changes associate with additional
trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric
cancer.
Br J Cancer. 2024 Sep 23. doi: 10.1038/s41416-024-02835. PubMedAbstract available
KANDA M, Kasahara Y, Shimizu D, Shinozuka T, et al Dual-modified antisense oligonucleotides targeting oncogenic protocadherin to
treat gastric cancer.
Br J Cancer. 2024 Sep 20. doi: 10.1038/s41416-024-02859. PubMedAbstract available
August 2024
GU Y, Sun M, Fang H, Shao F, et al Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant
chemotherapy and immunotherapy in gastric cancer.
Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02825. PubMedAbstract available
July 2024
FANG M, Lin Y, Xue C, Sheng K, et al The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric
cancer cells via induction of pyroptosis.
Br J Cancer. 2024 Jul 13. doi: 10.1038/s41416-024-02778. PubMedAbstract available
HARA Y, Baba Y, Oda E, Harada K, et al Presence of Fusobacterium nucleatum in relation to patient survival and an acidic
environment in oesophagogastric junction and gastric cancers.
Br J Cancer. 2024 Jul 12. doi: 10.1038/s41416-024-02753. PubMedAbstract available
ANGERILLI V, Sabella G, Simbolo M, Lagano V, et al Comprehensive genomic and transcriptomic characterization of high-grade
gastro-entero-pancreatic neoplasms.
Br J Cancer. 2024;131:159-170. PubMedAbstract available
June 2024
LI X, Xie G, Chen J, Wang Y, et al Tumour cell-derived serglycin promotes IL-8 secretion of CAFs in gastric cancer.
Br J Cancer. 2024 Jun 11. doi: 10.1038/s41416-024-02735. PubMedAbstract available
May 2024
MURPHY JD, Gadalla SM, Anderson LA, Rabkin CS, et al Autoimmune conditions and gastric cancer risk in a population-based study in the
United Kingdom.
Br J Cancer. 2024 May 22. doi: 10.1038/s41416-024-02714. PubMedAbstract available
March 2024
SUH YS, Lee J, George J, Seol D, et al RNA expression of 6 genes from metastatic mucosal gastric cancer serves as the
global prognostic marker for gastric cancer with functional validation.
Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02642. PubMedAbstract available
February 2024
SAITO T, Kurokawa Y, Fujitani K, Kawabata R, et al Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of
gastric cancer: a multicenter prospective observational study.
Br J Cancer. 2024 Feb 7. doi: 10.1038/s41416-023-02540. PubMedAbstract available
CECCHINI M, Cleary JM, Shyr Y, Chao J, et al NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in
previously treated metastatic gastric and gastroesophageal junction
adenocarcinoma.
Br J Cancer. 2024;130:476-482. PubMedAbstract available
GROSSER B, Emmerson J, Reitsam NG, Cunningham D, et al Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk
stratification of perioperative chemotherapy treated oesophagogastric cancer
patients from the MAGIC and the ST03 trial.
Br J Cancer. 2024;130:457-466. PubMedAbstract available
January 2024
WANG J, Sun N, Kunzke T, Shen J, et al Metabolic heterogeneity affects trastuzumab response and survival in
HER2-positive advanced gastric cancer.
Br J Cancer. 2024 Jan 24. doi: 10.1038/s41416-023-02559. PubMedAbstract available
CAI F, Yang X, Ma G, Wang P, et al EGLN3 attenuates gastric cancer cell malignant characteristics by inhibiting
JMJD8/NF-kappaB signalling activation independent of hydroxylase activity.
Br J Cancer. 2024 Jan 6. doi: 10.1038/s41416-023-02546. PubMedAbstract available
December 2023
KAMIYA H, Komatsu S, Takashima Y, Ishida R, et al Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to
PD-L1 in gastric cancer.
Br J Cancer. 2023 Dec 26. doi: 10.1038/s41416-023-02532. PubMedAbstract available
November 2023
ALLAN Z, Witts S, Tie J, Tebbutt N, et al The prognostic impact of peritoneal tumour DNA in gastrointestinal and
gynaecological malignancies: a systematic review.
Br J Cancer. 2023;129:1717-1726. PubMedAbstract available
August 2023
CHEN T, Li D, Wang Y, Shen X, et al Loss of NDUFS1 promotes gastric cancer progression by activating the
mitochondrial ROS-HIF1alpha-FBLN5 signaling pathway.
Br J Cancer. 2023 Aug 29. doi: 10.1038/s41416-023-02409. PubMedAbstract available
ANDO K, Nakamura Y, Kitao H, Shimokawa M, et al Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in
advanced gastric cancer (TP53MUT study).
Br J Cancer. 2023 Aug 2. doi: 10.1038/s41416-023-02378. PubMedAbstract available
July 2023
LIU X, Lv K, Wang J, Lin C, et al C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages
improves anti-PD-1 efficacy in gastric cancer.
Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02336. PubMedAbstract available
LEE JE, Kim KT, Shin SJ, Cheong JH, et al Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338. PubMedAbstract available
June 2023
DONG X, Fan J, Xie W, Wu X, et al Efficacy evaluation of chimeric antigen receptor-modified human peritoneal
macrophages in the treatment of gastric cancer.
Br J Cancer. 2023 Jun 29. doi: 10.1038/s41416-023-02319. PubMedAbstract available
April 2023
LIU DHW, Kim YW, Sefcovicova N, Laye JP, et al Tumour infiltrating lymphocytes and survival after adjuvant chemotherapy in
patients with gastric cancer: post-hoc analysis of the CLASSIC trial.
Br J Cancer. 2023 Apr 7. doi: 10.1038/s41416-023-02257. PubMedAbstract available
LAAKSONEN MA, Li S, Canfell K, MacInnis RJ, et al The future burden of oesophageal and stomach cancers attributable to modifiable
behaviours in Australia: a pooled cohort study.
Br J Cancer. 2023;128:1052-1069. PubMedAbstract available